Home
Profile
Manufacturing
Quality Control
Products
  Contact Us Careers Sitemap          
   
 
:: Research & Development
:: International Collaboration
:: Business Opportunities
:: Latest Events
:: Divisions At a Glance


  press_release_btn_otherspg :: Press Releases vline_separator

  :: In Licensing   inlicensing_btn__otherspg vline_separator

  outlicensing_btn_otherspg :: Out Licensing vline_separator

 
  Urokinase for Injection 2,50,000 IU
  Indications :
 

Coronary artery thrombosis (associated with an evolving transmural myocardial infarction).

Acute pulmonary embolism.

Deep vein thrombosis.

Peripheral vascular thrombo-embolism.

   
  Dosage :
 

Coronary artery thrombosis associated with evolving transmural myocardial infarction :
Within 6 hours after the onset of symptoms as IV.

Loading Dose : 4,400 IU per kg of body wt.

Maintenance Dose : 4,400 IU/kg/hour reconstituted in 200 ml of sterile physiological saline of 6-12 hrs.

Intracoronary Administration : Infusion at a rate of 6000 I.U. /min. (Max. dose = 10,000 I.U. /Kg of body weight).

Pulmonary Embolism DVT (Deep Vein Thrombosis & Peripheral Vascular Thrombo-embolism :

Loading Dose :
4,400 IU per kg of body wt. reconstituted in 15 ml of dextrose IV over 10 min.

Maintenance Dose : 4,400 IU/kg/hour reconstituted in 200 ml of sterile physiological saline of 8-12 hrs. The total duration of the treatment usually lasts 6 to 13 days.

Anticoagulant Therapy : Following treatment with urokinase, anticoagulants (Heparin) are recommended to prevent or minimize the follow-up thrombosis.

   
  Packing : 10 Vials of 2,50,000 IU
 



  Home | Careers | Site map | Contact Us



 
  All contents copyright © United Biotech (P) Limited, All rights reserved.